Objectives: To study the regulatory region of a constitutively expressed erm(A) gene in Streptococcus agalactiae clinical isolates.
Introduction
Streptococcus agalactiae or group B Streptococcus (GBS) is emerging as a cause of serious infection worldwide. GBS is one of the pathogens most frequently responsible for peripartum maternal and neonatal infections.
Aminopenicillin is recommended as first-line chemoprophylaxis and erythromycin and clindamycin are the second-line choice of drug used in penicillin-hypersensitive patients. 1 Whereas clinical isolates of S. agalactiae usually remain susceptible to penicillins, the rates of erythromycin resistance among GBS isolates have been increasing in recent years. 2, 3 Two principal mechanisms have been found to be responsible for acquired erythromycin resistance in S. agalactiae, namely target site modification and active efflux. Drug efflux, also referred to as the M phenotype, is encoded by the mef(A) gene and results in low-level resistance to erythromycin but not to clindamycin. Target site modification is mostly based on N 6 dimethylation of an adenine residue (A2058) in the peptidyl transferase circle of 23S rRNA domain V through the action of a family of enzymes encoded by erm class genes. Methylation results in reduced binding and cross-resistance to macrolide, lincosamide and streptogramin B (MLS) antibiotics. It is well established that MLS resistance can be expressed either constitutively (cMLS phenotype) or by induction (iMLS phenotype) in streptococci and in S. agalactiae it is mediated by two classes of methylase genes, the conventional erm(B) and that which was recently described in S. pyogenes, erm(A). [4] [5] [6] Information on the molecular basis of constitutive erm(A) gene expression is derived from studies of S. pyogenes strains which showed that changes in the sequence of the regulatory region of the methylase gene are associated with a constitutive phenotype. To our knowledge, there is no information available concerning S. agalactiae strains. However, S. agalactiae strains with phenotypes similar to S. pyogenes constitutively expressing erm(A) have also been reported. 1, 7 
Materials and methods

Bacterial strains
A total of 35 clinical isolates of erythromycin-resistant S. agalactiae were studied. Of these, 30 isolates were more resistant to clindamycin than to erythromycin. Isolates were obtained from skin and soft tissues (n = 13), urine (n = 10), vagina (n = 4) and various other sites (n = 8).
Isolates were identified by a commercial latex agglutination technique (Slidex Strepto B; bioMérieux, Marcy L'É toile, France).
Determination of macrolide resistance phenotype
The erythromycin-clindamycin double-disc test was carried out as described by Seppälä et al. 8 Commercial discs (Oxoid Ltd, Basingstoke, UK) of erythromycin (15 mg) and clindamycin (2 mg) were used.
Susceptibility tests
Antimicrobial susceptibility testing was performed by the standard agar dilution method.
9 Agar plates were incubated overnight at 37 C in ambient air. The following organisms were included as control strains: Streptococcus pneumoniae ATCC 49619 and Enterococcus faecalis ATCC 29212.
Antibiotics
Erythromycin and clindamycin were provided by Sigma Chemical Co. 
Detection of erythromycin resistance genes
The erm(B) and mef(A) genes were detected by PCR with the oligonucleotide primer pairs reported by Sutcliffe et al. 10 The erm(A) gene was detected with primers designed by Seppälä et al.
11 DNA preparation and amplification, and electrophoresis of PCR products were carried out by established procedures. [10] [11] [12] Briefly, PCR mixtures of 50 mL contained 1. C for 1 min. PCR products were resolved by electrophoresis on 1.5% agarose gels.
Analysis of the regulatory regions of erm(A)
The sequences of the erm attenuator were amplified from bacterial DNA by PCR as described by Fines et al. 13 PCR products were resolved by electrophoresis on 1.5% agarose gels; the expected size was 340 bp. PCR products were then purified on UltraClean PCR Clean-up columns (MO BIO Laboratories Inc., Solana Beach, CA, USA) and sequenced on an ABI PRISM 310 automated sequencer (Applied Biosystems, Foster City, CA, USA).
Typing methods
Epidemiological relatedness of all isolates was studied by randomly amplified polymorphic DNA (RAPD) as described elsewhere. 12, 14 Molecular typing was performed at least twice on each isolate with two different primers (M13: TTATGTAAAAACGACGGCCAGT and H2: CCTCCCGCCACC) and Ready-To-Go Analysis Beads (Pharmacia Biotech, Piscataway, NJ, USA). Fifty nanograms of purified DNA was used per assay. After agarose gel electrophoresis, the gel was stained with ethidium bromide and visualized under UV light. Fingerprint patterns were photographed and compared visually. Strains showing identical profiles were considered to be clonal.
Results
Identification of macrolide resistance phenotypes
On the basis of the erythromycin/clindamycin double disc test, four strains were assigned to the M phenotype, one (HCSC 1134) was assigned to the iMLS phenotype, and 30 were assigned to the cMLS phenotype ( Table 1) .
The MICs of two 14-membered (erythromycin and clarithromycin), one 15-membered (azithromycin), and one 16-membered (josamycin) macrolide, clindamycin, the ketolide telithromycin and quinupristin-dalfopristin were determined and compared (Table 1) . Homogeneous susceptibility patterns were observed for isolates of the cMLS phenotype in all but one of the strains (HCSC 407). This pattern of resistance to MLS antibiotics was characterized by high resistance to clindamycin (range 16->256 mg/L) and low resistance to erythromycin (range 1-16 mg/L). MICs for clarithromycin ranged from 2 to 32 mg/L, for azithromycin from 1 to 128 mg/L, and for josamycin from 2 to 64 mg/L. All isolates were susceptible to telithromycin and quinupristin-dalfopristin (Table 1) .
Erythromycin resistance genes
The presence of the erythromycin resistance genes erm(B), erm(A) and mef(A) in the MLS-resistant strains was investigated primarily by PCR. The erm(B) gene was detected in four strains [always associated with the erm(A) gene], and the mef(A) gene was detected in all strains with the M-resistant phenotype.
The situation was initially less clear for the erm(A) gene. With the primer pair described by Seppälä et al., 11 an amplicon of the expected size was detected in 27 strains (26 cMLSB and one iMLSB), whereas in four isolates, a longer amplicon was obtained. Attenuators of erm(A) were amplified by PCR with a specific primer 13 in all erm(A)-positive isolates and similar results were found. One of the amplification products obtained from 27 isolates was of the expected size (340 bp) and another amplicon from four isolates was larger than expected (1204 bp). The overall results of the distribution of erythromycin resistance genes among the S. agalactiae test strains are summarized in Table 1 .
Analysis of the regulatory regions of erm(A)
Attenuators of the erm(A) region of S. agalactiae HCSC 1134 and of 30 isolates with a clindamycin MIC higher than that of erythromycin were purified and sequenced. The erm(A) attenuator sequence of HCSC 1134 showed 100% identity with the corresponding previously determined sequence. 11 All the other isolates showed alterations in the upstream region of the gene. Most of the changes were in the ORF of the second leader peptide (LP2) in the erm(A) attenuator. The four isolates with a longer amplicon carried an insertion in position 90 of LP2. Sequencing of the insertion fragment showed 98% identity with SAG2002, 15 and with several other insertion sequences, IS1381 and the transposase gene (GenBank access numbers: AE014282, AE014262, AE014258, AE014236, AE014216, AE014203, AF367974, AY598359, AF064785). Strains with longer amplicons had an identical 864 bp insertion. The sequence flanking the point of insertion was duplicated to form two repeats in the same orientation at the ends of the transposon (Figure 1 ). With the exception of strain HCSC636, all the other clindamycin-resistant mutants showed an A137C (Q15P) mutation. Several additional mutations appear in most of the isolates (Table 1) .
Clonal relationship of clindamycin-resistant mutants
A total of 19 different RAPD patterns were observed among the 35 isolates under study. Three of the four isolates with an insertion in the attenuator region shared the same clonal pattern. Thirteen different RAPD patterns were observed among the other isolates with an MIC to clindamycin higher than that of erythromycin. One profile appeared in nine isolates, a different profile appeared in four isolates and two different profiles appeared in two isolates each. All of the remaining nine isolates had individual patterns. Isolates with the M phenotype also showed four different RAPD patterns.
Discussion
The attenuator region of the erm group has been studied in several bacterial groups, 13, 16, 17 but not in S. agalactiae. In all previous studies, several deletion, insertion and point mutations are responsible for constitutive expression of erm-type genes.
Regulation of erm(A) by structural alterations in the translational attenuator was first found in Staphylococcus aureus. 18 The structural alterations observed included deletions, different tandem duplications, and point mutation as well as insertion. Since then, similar results have been obtained with S. intermedius, 17 S. pneumoniae 19 and S. pyogenes. 20 All the alterations observed either completely prevented the formation of mRNA secondary structures in the erm(A) regulatory region or favoured the formation of those mRNA secondary structures that allowed translation of the erm(A) transcripts.
In our study, we selected S. agalactiae clinical isolates with clindamycin MICs higher than those of erythromycin. This phenomenon has been detected previously by our group, 12 and by other authors, 1, 7 and in all cases, the strains carried the erm(A) gene. The attenuator of erm(A) has been studied in S. pyogenes and it is known to contain two ORFs, each preceded by a ribosomebinding site (RBS) which could encode two leader peptides, LP1 and LP2, with 15 and 19 amino acids, respectively. In addition, the mRNA sequence contains a series of inverted repeats that could form stem-loop structures that sequester the RBS and the initiation codons of the methylase gene. 13 Destabilization of the stem-loop would lead to the translation of the erm(A) gene. Thus, mutations in the gene attenuator might be responsible for constitutive expression of methylase.
A comparison of sequences between one of our inducible erm(A) strains and 30 clindamycin-resistant isolates showed that all constitutive strains possessed mutations in the attenuator region. The most frequent change occurred in position 137, as has been described in some S. pyogenes strains. 21 This change has been proven to be enough to decrease the stability of the stem-loop and allow constitutive expression of the methylase gene. Even so, some other mutations have been detected.
The presence of IS1381 and transposase gene in two strains indicated that the attenuator region is susceptible to this type of alteration. The sequence of serotype V, S. agalactiae strain 2603V/R, identified several of these mobile genetic elements located elsewhere in its genome. 15 This kind of sequence is also identified in other group B streptococci. 22 The possibility of inserting mobile elements in the attenuator region and distribution of these elements in the genome of streptococci gives cause for concern.
Molecular typing of our GBS indicated that attenuator changes are not unusual, because most of the S. agalactiae studied are not related to each other. The number of clonal origins, types of mutation and frequency of IS1381 elements have to be taken into account as factors which contributed to selection of constitutively resistant derivatives. Studies developed with S. pyogenes revealed that constitutive mutants could be selected on agar medium containing clindamycin. No data are yet available for S. agalactiae strains but similarities between the two species have led us to suppose that clindamycin may be responsible for some genetic alterations. Therefore the use of clindamycin to treat infections caused by streptococci strains harbouring an inducible erm(A) gene should be discouraged. It would be necessary to check the role of some other macrolidelincosamide-streptogramin compounds as inducers of erm(A) promoter alterations.
